India's Semaglutide Market Set for Generic Boom as Patents Expire, Over 50 Brands Lined Up for Launch, See Full List Farhat Nasim4 March 2026 10:15 PM ISTNew Delhi: The expiry of semaglutide's key patent in India in March 2026 is ushering in a tsunami of generic versions of the blockbuster diabetes and...
Lupin Receives USFDA EIR with VAI Status for Goa Manufacturing Plant Kajal Rajput27 Feb 2026 7:08 PM ISTNew Delhi: Drug maker Lupin on Friday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its Goa-based...
SC Seeks Centre, DCGI Response on Micro Labs' Plea Against Anti-Diabetic FDC Ban Susmita Roy26 Feb 2026 10:26 PM ISTNew Delhi: The Supreme Court sought responses from the Union government and the Drug Controller General of India regarding an appeal filed by Micro...
Lupin Secures USFDA Nod for Epilepsy Drug Brivaracetam in US Parthika Patel25 Feb 2026 2:01 PM ISTMumbai: Mumbai-based pharmaceutical major Lupin Limited has received approval from the US Food and Drug Administration (USFDA) for its Brivaracetam...
Lupin Gets Zero USFDA Observations for Nagpur Plant sheeba farhat15 Feb 2026 11:30 AM ISTMumbai: Lupin Limited has announced the successful completion of a United States Food and Drug Administration (USFDA) inspection at its Nagpur...
Lupin Appoints Dr Kushkumar Thakare as Manager, Medical Affairs for India Region Susmita Roy13 Feb 2026 1:21 PM ISTNew Delhi: Lupin has announced the appointment of Dr Kushkumar Thakare as Manager, Medical Affairs, India Region Formulations, reinforcing the...
Lupin Gets 1 Observation for Tarapur Facility After USFDA cGMP Inspection sheeba farhat12 Feb 2026 11:17 PM ISTMumbai: Pharma major Lupin has announced the completion of a cGMP inspection carried out by the United States Food and Drug Administration (USFDA) at...
Lupin's Indore Plant Gets 6 Observations After USFDA Inspection sheeba farhat11 Feb 2026 8:26 PM ISTMumbai: Pharma major Lupin has announced the completion of a United States Food and Drug Administration (USFDA) inspection at its Pithampur Unit-2...
Lupin Settles Mirabegron Patent Dispute With Astellas for USD 90 Million, Clears US Sales sheeba farhat10 Feb 2026 8:00 PM ISTUnder the agreement, Lupin and its U.S. unit will pay Astellas a USD 75 million upfront payment and per-unit licensing fees on Mirabegron sales...
Lupin signs licensing pact with Gan & Lee Pharma for GLP-1 receptor agonist Bofanglutide Ruchika Sharma30 Dec 2025 11:30 AM ISTMumbai: Global pharma major Lupin Limited has announced that it has entered into an exclusive License, Supply and Distribution agreement with Gan...
Eli Lilly, Novo Nordisk race to lock in India obesity drug market Ruchika Sharma26 Dec 2025 4:23 PM ISTHyderabad: Global pharma heavyweights Eli Lilly and Novo Nordisk are racing to lock in market leadership in India’s blooming obesity drug market,...
Lupin, Neopharmed sign licensing pact for Gastro brand Plasil in Brazil, Philippines Ruchika Sharma18 Dec 2025 5:23 PM ISTPlasil is widely acknowledged for its efficacy in treating nausea, vomiting, and motility disorders.
